Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 15 | 2025 | 1405 | 2.670 |
Why?
|
| Memory, Short-Term | 8 | 2019 | 150 | 2.300 |
Why?
|
| Attention | 4 | 2019 | 202 | 1.470 |
Why?
|
| Mathematics | 5 | 2016 | 93 | 1.410 |
Why?
|
| Neuropsychological Tests | 15 | 2024 | 988 | 1.120 |
Why?
|
| Cognition Disorders | 5 | 2020 | 578 | 1.060 |
Why?
|
| Mutism | 2 | 2024 | 32 | 1.030 |
Why?
|
| Proton Therapy | 3 | 2022 | 151 | 1.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2024 | 818 | 0.930 |
Why?
|
| Cerebellar Neoplasms | 3 | 2024 | 461 | 0.910 |
Why?
|
| Cancer Survivors | 4 | 2025 | 251 | 0.910 |
Why?
|
| Mathematical Concepts | 2 | 2015 | 7 | 0.910 |
Why?
|
| Cognition | 6 | 2022 | 815 | 0.850 |
Why?
|
| Memory Disorders | 2 | 2018 | 235 | 0.830 |
Why?
|
| Adaptation, Psychological | 2 | 2024 | 453 | 0.810 |
Why?
|
| Learning | 2 | 2018 | 375 | 0.780 |
Why?
|
| Spinal Dysraphism | 4 | 2015 | 274 | 0.750 |
Why?
|
| Medulloblastoma | 2 | 2024 | 571 | 0.740 |
Why?
|
| Survivors | 5 | 2022 | 358 | 0.720 |
Why?
|
| Reading | 5 | 2016 | 79 | 0.710 |
Why?
|
| Meningomyelocele | 2 | 2015 | 255 | 0.630 |
Why?
|
| Child Behavior Disorders | 1 | 2019 | 70 | 0.620 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 253 | 0.620 |
Why?
|
| Developmental Disabilities | 4 | 2019 | 744 | 0.610 |
Why?
|
| Radiotherapy Dosage | 2 | 2025 | 232 | 0.610 |
Why?
|
| Child | 30 | 2025 | 25828 | 0.610 |
Why?
|
| Social Class | 1 | 2019 | 207 | 0.560 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 72 | 0.560 |
Why?
|
| Space Perception | 2 | 2014 | 63 | 0.520 |
Why?
|
| Craniospinal Irradiation | 3 | 2023 | 66 | 0.520 |
Why?
|
| Adolescent | 18 | 2025 | 20528 | 0.470 |
Why?
|
| Motor Skills | 1 | 2015 | 85 | 0.460 |
Why?
|
| Memory | 1 | 2018 | 358 | 0.450 |
Why?
|
| Verbal Learning | 3 | 2022 | 72 | 0.430 |
Why?
|
| Visual Perception | 1 | 2014 | 136 | 0.400 |
Why?
|
| Male | 26 | 2025 | 65472 | 0.360 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2017 | 238 | 0.360 |
Why?
|
| Child, Preschool | 12 | 2025 | 14862 | 0.360 |
Why?
|
| Female | 26 | 2025 | 71382 | 0.340 |
Why?
|
| Parents | 1 | 2017 | 1073 | 0.320 |
Why?
|
| Goals | 1 | 2010 | 134 | 0.310 |
Why?
|
| Dyslexia | 1 | 2009 | 30 | 0.300 |
Why?
|
| Humans | 33 | 2025 | 133147 | 0.290 |
Why?
|
| Brain Injuries | 1 | 2012 | 717 | 0.270 |
Why?
|
| Brain | 3 | 2025 | 3223 | 0.250 |
Why?
|
| Protons | 2 | 2022 | 98 | 0.240 |
Why?
|
| Organs at Risk | 1 | 2025 | 41 | 0.230 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2024 | 63 | 0.200 |
Why?
|
| Longitudinal Studies | 4 | 2016 | 1514 | 0.200 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2024 | 197 | 0.190 |
Why?
|
| Sleep Wake Disorders | 2 | 2021 | 188 | 0.190 |
Why?
|
| Problem Solving | 3 | 2013 | 66 | 0.190 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 56 | 0.190 |
Why?
|
| Methotrexate | 1 | 2024 | 355 | 0.190 |
Why?
|
| Survivorship | 1 | 2022 | 44 | 0.190 |
Why?
|
| Achievement | 2 | 2013 | 33 | 0.180 |
Why?
|
| Cognitive Dysfunction | 2 | 2023 | 316 | 0.180 |
Why?
|
| Cerebellar Diseases | 1 | 2022 | 81 | 0.180 |
Why?
|
| Emotions | 1 | 2024 | 366 | 0.180 |
Why?
|
| Language Development Disorders | 1 | 2022 | 179 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 216 | 0.170 |
Why?
|
| Neuropsychology | 1 | 2020 | 22 | 0.170 |
Why?
|
| Pain | 1 | 2022 | 469 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 77 | 0.150 |
Why?
|
| Relative Biological Effectiveness | 1 | 2018 | 8 | 0.150 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 72 | 0.150 |
Why?
|
| Transition to Adult Care | 1 | 2020 | 115 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 212 | 0.140 |
Why?
|
| Cisplatin | 1 | 2019 | 285 | 0.140 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 159 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1307 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 294 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 168 | 0.140 |
Why?
|
| Models, Psychological | 2 | 2020 | 145 | 0.140 |
Why?
|
| Down Syndrome | 1 | 2020 | 231 | 0.140 |
Why?
|
| Hippocampus | 2 | 2025 | 860 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2018 | 256 | 0.140 |
Why?
|
| Organ Size | 1 | 2018 | 463 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 398 | 0.130 |
Why?
|
| Risk Factors | 2 | 2022 | 10930 | 0.130 |
Why?
|
| Glioma | 1 | 2021 | 535 | 0.120 |
Why?
|
| Fatigue | 3 | 2022 | 199 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 5434 | 0.120 |
Why?
|
| Prevalence | 1 | 2022 | 2628 | 0.120 |
Why?
|
| Educational Status | 1 | 2016 | 294 | 0.120 |
Why?
|
| Neuroimaging | 1 | 2018 | 376 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3169 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2013 | 1033 | 0.110 |
Why?
|
| Concept Formation | 1 | 2013 | 27 | 0.110 |
Why?
|
| Pattern Recognition, Visual | 1 | 2013 | 28 | 0.110 |
Why?
|
| Depression | 1 | 2022 | 1362 | 0.100 |
Why?
|
| Comprehension | 1 | 2013 | 80 | 0.100 |
Why?
|
| Bone Diseases | 1 | 2012 | 45 | 0.100 |
Why?
|
| Orthopedics | 1 | 2012 | 78 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1849 | 0.090 |
Why?
|
| Child Development | 1 | 2013 | 286 | 0.090 |
Why?
|
| Prognosis | 3 | 2024 | 5030 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3863 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17520 | 0.060 |
Why?
|
| Frontal Lobe | 1 | 2025 | 121 | 0.060 |
Why?
|
| Intelligence | 1 | 2023 | 107 | 0.050 |
Why?
|
| Intelligence Tests | 1 | 2022 | 63 | 0.050 |
Why?
|
| Time Factors | 1 | 2012 | 6541 | 0.050 |
Why?
|
| Social Adjustment | 1 | 2022 | 79 | 0.050 |
Why?
|
| Young Adult | 3 | 2020 | 9917 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 3087 | 0.050 |
Why?
|
| Adult | 2 | 2019 | 31608 | 0.040 |
Why?
|
| Executive Function | 1 | 2021 | 124 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 32 | 0.040 |
Why?
|
| Research | 1 | 2022 | 272 | 0.040 |
Why?
|
| Age Factors | 2 | 2021 | 2954 | 0.040 |
Why?
|
| Professional Role | 1 | 2020 | 74 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1173 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 370 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2019 | 234 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2019 | 182 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2025 | 3406 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1467 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 1469 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 471 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2020 | 404 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1236 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1837 | 0.030 |
Why?
|
| Phonetics | 1 | 2013 | 45 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1340 | 0.030 |
Why?
|
| Reaction Time | 1 | 2013 | 169 | 0.030 |
Why?
|
| Epilepsy | 1 | 2020 | 898 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 3360 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 5188 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3734 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3411 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 256 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 6570 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 808 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 2092 | 0.020 |
Why?
|
| Infant | 1 | 2021 | 13235 | 0.010 |
Why?
|